Lexeo Therapeutics, Inc. Quarterly Nonoperating Income (Expense) in USD from Q3 2022 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
Lexeo Therapeutics, Inc. quarterly/annual Nonoperating Income (Expense) history and growth rate from Q3 2022 to Q2 2024.
  • Lexeo Therapeutics, Inc. Nonoperating Income (Expense) for the quarter ending June 30, 2024 was $2.31M, a 333% increase year-over-year.
  • Lexeo Therapeutics, Inc. Nonoperating Income (Expense) for the twelve months ending June 30, 2024 was $4.87M.
  • Lexeo Therapeutics, Inc. annual Nonoperating Income (Expense) for 2023 was $2.12M, a 72% increase from 2022.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Quarterly (USD)
Nonoperating Income (Expense), YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $4.87M $2.31M +$1.78M +333% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-12
Q1 2024 $3.1M $1.61M +$976K +154% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-09
Q4 2023 $2.12M $787K Oct 1, 2023 Dec 31, 2023 10-K 2024-03-11
Q3 2023 $165K -$262K -61.4% Jul 1, 2023 Sep 30, 2023 10-Q 2023-12-11
Q2 2023 $534K Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-12
Q1 2023 $633K Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-09
Q3 2022 $427K Jul 1, 2022 Sep 30, 2022 10-Q 2023-12-11
* An asterisk sign (*) next to the value indicates that the value is likely invalid.